‘It’s very frustrating’: ovarian cancer patient waiting on potential approval of new treatment

27 July 2017 - Seventy-five women are diagnosed with ovarian cancer in Saskatchewan each year, and fifty-five lose their lives.  ...

Read more →

Canadians living with multiple myeloma need access to therapies now

 4 July 2017 - Multiple myeloma, commonly referred to as myeloma, is an incurable cancer of the plasma cells found in ...

Read more →

Public funding of approved lung cancer treatments needed now

7 June 2017 - The Canadian Cancer Survivor Network and Lung Cancer Canada are calling on government and industry to ...

Read more →

CADTH publishes final outcome for Gazyva for new indication

2 June 2017 - The Canadian pERC has recommended the funding of obinutuzumab (Gazyva) for use by adults with non-Hodgkin's ...

Read more →

Pan-Canadian Oncology Drug Review recommendation supports the use of Tagrisso (osimertinib) as the standard of care for T790M mutated non-small-cell lung cancer

8 May 2017 - AstraZeneca is committed to rapid and collaborative discussions with pan-Canadian Pharmaceutical Alliance and provinces to get ...

Read more →

Engaging specialist oncologists in the assessment of oncology drugs in Canada

1 May 2017 - The assessment of new cancer drugs in Canada increasingly engages specialist oncology physicians. This has not always ...

Read more →

Cancer care drug costs concern group

26 April 2017 - Jennifer McGrady has never even touched a cigarette. ...

Read more →

pERC publishes initial recommendation for Roche's Gazyva

30 March 2017 - The outcome relates to the use of obinutuzumab in combination with chemotherapy followed by obinutuzumab monotherapy ...

Read more →

pERC publishes final recommendation for Sanofi Genzyme's Caprelsa

30 March 2017 -  The recommendation relates to the use of vandetanib for the treatment of symptomatic and/or progressive medullary ...

Read more →

pERC publishes final outcome for Amgen's Kyprolis

30 March 2017 - The outcome relates to the use of carfilzomib in combination with dexamethasone by patients with relapsed ...

Read more →

Roche withdraws submission for Avastin

28 March 2017 - Roche was seeking a positive CADTH recommendation for the use of bevacizumab in combination with pemetrexed ...

Read more →

What aspects of an economic evaluation are commercially sensitive?

6 March 2017 - Interesting insights from the pCODR Initial Economic Guidance Report for alectinib hydrochloide (Alecensaro). ...

Read more →

Ontario cancer patient 'in limbo' over chemotherapy drug shortage

7 March 2017 - A cancer patient who was told last week that she may not receive her much-needed chemotherapy ...

Read more →

CADTH publishes initial recommendations for three medicines for non-small-cell lung cancer

3 March 2016 - The outcome for three medicines, ceritinib (Zykadia), osimertinib mesylate (Tagrisso) and alectinib hydrochloride (Alecensaro), demonstrate the ...

Read more →

AbbVie withdraws submission for Venclexta

10 January 2017 - Abbvie was seeking funding for venetoclax when used as a treatment for patients with chronic lymphocytic ...

Read more →